Since we observed NKG2D CAR T cells were also effective against T-ALL (especially against Jurkat cells) and there are still no effective CAR T cell therapies available to treat this disease, we set the focus in exploring the potential use of NKG2D CAR T cells as treatment for T-ALL using Jurkat cells. Here, KLRK1 is linked to acute lymphoblastic leukemia.